Progyny (NASDAQ:PGNY) Stock: Insider Mark Livingston Sells 2,139 Shares

by · The Markets Daily

Progyny, Inc. (NASDAQ:PGNY – Get Free Report) CFO Mark Livingston sold 2,139 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $30.00, for a total transaction of $64,170.00. Following the sale, the chief financial officer directly owned 70,314 shares in the company, valued at approximately $2,109,420. The trade was a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Up 1.4%

NASDAQ:PGNY opened at $34.84 on Friday. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $35.50. The stock has a market capitalization of $2.67 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 2.40 and a beta of 0.97. The stock’s 50-day moving average price is $27.45 and its 200-day moving average price is $24.59.

Progyny (NASDAQ:PGNY – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.21. The firm had revenue of $341.25 million during the quarter, compared to analyst estimates of $340.76 million. Progyny had a return on equity of 19.82% and a net margin of 6.80%. Progyny’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 EPS. Sell-side analysts expect that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

PGNY has been the subject of several research reports. Truist Financial boosted their price target on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. raised their target price on shares of Progyny from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, August 21st. Citizens Jmp boosted their price target on shares of Progyny from $33.00 to $38.00 and gave the company a “market outperform” rating in a research report on Thursday. Leerink Partners lifted their target price on shares of Progyny from $37.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 19th. Eleven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.92.

Get Our Latest Analysis on Progyny

More Progyny News

Here are the key news stories impacting Progyny this week:

  • Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
  • Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
  • Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
  • Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio purchased a new stake in shares of Progyny in the 2nd quarter valued at $29,000. Nykredit A S acquired a new position in Progyny during the 2nd quarter worth about $38,000. IFP Advisors Inc boosted its holdings in Progyny by 376.0% during the 2nd quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock valued at $57,000 after acquiring an additional 1,549 shares during the period. Toth Financial Advisory Corp purchased a new position in Progyny during the 2nd quarter valued at about $65,000. Finally, Integrated Wealth Concepts LLC purchased a new position in Progyny during the 2nd quarter valued at about $74,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

(Get Free Report)

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.

See Also